REGN Q4 2017 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.6B+29.0% YoY

Gross Profit

$1.4B91.1% margin

Operating Income

$539M34.0% margin

Net Income

$174M11.0% margin

EPS (Diluted)

$1.49

QoQ Revenue Growth

+5.4%

Cash Flow

Operating Cash Flow

$567M

Free Cash Flow

$459M

Stock-Based Comp.

$127M

Balance Sheet

Total Assets

$8.8B

Total Liabilities

$2.6B

Stockholders' Equity

$6.1B

Cash & Equivalents

$813M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.6B	$1.2B	+29.0%
Gross Profit	$1.4B	$1.1B	+28.4%
Operating Income	$539M	$347M	+55.3%
Net Income	$174M	$253M	-31.4%

Revenue Segments

Antibody Collaboration

$126M63%

Immuno-oncology Agreement

$73M37%